Artbio CEO Emanuele Ostuni (L) and F-Prime partner Alex Pasteur

Art­bio emerges with $23M to make ra­di­oli­gand ther­a­pies for prostate can­cer, with field still in 'ear­ly days'

An­oth­er start­up is en­ter­ing the ra­dio­phar­ma mar­ket, backed by F-Prime Cap­i­tal and Omega Funds, with an ex­pe­ri­enced team from No­var­tis and Bay­er.

Art­bio is launch­ing with $23 mil­lion and a pipeline of al­pha ra­di­oli­gand ther­a­pies, in­clud­ing a PS­MA-di­rect­ed prostate can­cer pro­gram. It’s an area of on­col­o­gy tar­get­ed by oth­ers in the field, in­clud­ing No­var­tis’ Plu­vic­to — which ran in­to sup­ply is­sues this win­ter — as well as the re­cent­ly de­buted Con­ver­gent Ther­a­peu­tics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.